These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital. Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818 [TBL] [Abstract][Full Text] [Related]
26. Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. Thompson K; Menzies S; Muckenthaler M; Torti FM; Wood T; Torti SV; Hentze MW; Beard J; Connor J J Neurosci Res; 2003 Jan; 71(1):46-63. PubMed ID: 12478613 [TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. Jiménez-Jiménez FJ; Molina JA; Aguilar MV; Meseguer I; Mateos-Vega CJ; González-Muñoz MJ; de Bustos F; Martínez-Salio A; Ortí-Pareja M; Zurdo M; Martínez-Para MC J Neural Transm (Vienna); 1998; 105(4-5):497-505. PubMed ID: 9720977 [TBL] [Abstract][Full Text] [Related]
28. Biomarkers of iron metabolism are independently associated with impaired glucose metabolism and type 2 diabetes: the KORA F4 study. Huth C; Beuerle S; Zierer A; Heier M; Herder C; Kaiser T; Koenig W; Kronenberg F; Oexle K; Rathmann W; Roden M; Schwab S; Seissler J; Stöckl D; Meisinger C; Peters A; Thorand B Eur J Endocrinol; 2015 Nov; 173(5):643-53. PubMed ID: 26294793 [TBL] [Abstract][Full Text] [Related]
30. Antioxidant and inflammatory biomarkers for the identification of prodromal Parkinson's disease. Campolo J; De Maria R; Cozzi L; Parolini M; Bernardi S; Proserpio P; Nobili L; Gelosa G; Piccolo I; Agostoni EC; Trivella MG; Marraccini P J Neurol Sci; 2016 Nov; 370():167-172. PubMed ID: 27772753 [TBL] [Abstract][Full Text] [Related]
31. Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication. Buhmann C; Arlt S; Kontush A; Möller-Bertram T; Sperber S; Oechsner M; Stuerenburg HJ; Beisiegel U Neurobiol Dis; 2004 Feb; 15(1):160-70. PubMed ID: 14751781 [TBL] [Abstract][Full Text] [Related]
32. Association between sex, systemic iron variation and probability of Parkinson's disease. Mariani S; Ventriglia M; Simonelli I; Bucossi S; Siotto M; Donno S; Vernieri F; Squitti R Int J Neurosci; 2016; 126(4):354-60. PubMed ID: 26000822 [TBL] [Abstract][Full Text] [Related]
33. Oxidative and nitrosative stress in serum of patients with Parkinson's disease. Çubukçu HC; Yurtdaş M; Durak ZE; Aytaç B; Güneş HN; Çokal BG; Yoldaş TK; Durak İ Neurol Sci; 2016 Nov; 37(11):1793-1798. PubMed ID: 27423450 [TBL] [Abstract][Full Text] [Related]
34. Lymphoproliferation Impairment and Oxidative Stress in Blood Cells from Early Parkinson's Disease Patients. Vida C; Kobayashi H; Garrido A; Martínez de Toda I; Carro E; Molina JA; De la Fuente M Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30759742 [TBL] [Abstract][Full Text] [Related]
35. Lymphocyte vitamin C levels as potential biomarker for progression of Parkinson's disease. Ide K; Yamada H; Umegaki K; Mizuno K; Kawakami N; Hagiwara Y; Matsumoto M; Yoshida H; Kim K; Shiosaki E; Yokochi T; Harada K Nutrition; 2015 Feb; 31(2):406-8. PubMed ID: 25592020 [TBL] [Abstract][Full Text] [Related]
36. Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk. Costa-Mallen P; Zabetian CP; Agarwal P; Hu SC; Yearout D; Samii A; Leverenz JB; Roberts JW; Checkoway H Parkinsonism Relat Disord; 2015 Sep; 21(9):1087-92. PubMed ID: 26228081 [TBL] [Abstract][Full Text] [Related]
37. Chronic thromboembolic pulmonary hypertension is not associated with iron overload. Xi Q; Liu Z; Liu W; Zhao Z; Luo Q; Huang Z Cardiovasc Pathol; 2015; 24(2):76-9. PubMed ID: 25449047 [TBL] [Abstract][Full Text] [Related]
38. Impairment of dynamic thiol-disulphide homeostasis in patients with idiopathic Parkinson's disease and its relationship with clinical stage of disease. Vural G; Gumusyayla S; Bektas H; Deniz O; Alisik M; Erel O Clin Neurol Neurosurg; 2017 Feb; 153():50-55. PubMed ID: 28027505 [TBL] [Abstract][Full Text] [Related]
39. Dysregulation of body antioxidant content is related to initiation and progression of Parkinson's disease. Fattah A; Amiri F; Mohammadian M; Alipourfard I; Valilo M; Taheraghdam A; Hemmati-Dinarvand M Neurosci Lett; 2020 Sep; 736():135297. PubMed ID: 32771603 [TBL] [Abstract][Full Text] [Related]